← Leaderboards
Larry Tjoelker
Macrogenics, Inc.
$471,018
Attributed
$471,018
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $254.1K · FY2021–22$500K$375K$250K$125K$0
'21
'22
Funding mix
By agency
NIH$471,018 · 2
By mechanism
R21$371,018 · 1
R43$100,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cytotoxic Agent”
- David Heimbrook · Leidos Biomedical Research, Inc.$61,051,089
- Philip J Disaia · University Of California Irvine$58,513,103
- Brenda J. Weigel · University Of Minnesota$36,792,183
- Walter John Curran · Thomas Jefferson University$26,641,549
- Douglas F Nixon · J. David Gladstone Institutes$26,316,237
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$20,277,168
Research focus
Cytotoxic AgentDrug DevelopmentAdverse OutcomeAntibodiesAntibody-Drug ConjugatesDisease RemissionAlkylating AgentsApplications GrantsAvidityBaseB-Cell Acute Lymphoblastic LeukemiaB-Cell DevelopmentB-Cell Precursor Acute Lymphoblastic Leukemia CellAdultAnticancer ActivityB-LymphocytesCancer CellCell LineCellsChemotherapyChildhood LeukemiaCombatCrosslinkDrug Kinetics
Grant awards (3)
Eliminating B Cell Precursor Acute Lymphoblastic Leukemia by Targeting the Uniquely Specific Pre-B Cell Receptor$254,143
R21 · FY2022 · CA · contact PI
Eliminating B Cell Precursor Acute Lymphoblastic Leukemia by Targeting the Uniquely Specific Pre-B Cell Receptor$116,875
R21 · FY2021 · CA · contact PI
Melanoma Proteins in Serum and Urine$100,000
R43 · FY2004 · CA